RegeneRx Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development of a novel therapeutic peptide, Thymosin beta 4 (TB4), for tissue and organ protection, repair, and regeneration. The Company has formulated TB4 into three distinct product candidates in clinical development: RGN-259, RGN-352 and RGN-137. RGN-259 is a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease or other pathology. RGN-259 is in phase three clinical trials in the United States and EU for the treatment of neurotrophic keratitis, an orphan indication. RGN-352 is an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, organ damage associated with COVID-19, and other medical indications that may be treated by systemic administration. RGN-137 is a topical gel for dermal wounds and reduction of scar tissue. It has active partnerships in four territories: North America, Europe, China and Pan Asia.